Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01340482 · ClinicalTrials.gov registry record · Phase 1
A Repeated Study of KRN23 in Adults With X-Linked Hypophosphatemia
A Phase 1 study, sponsored by Kyowa Kirin Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT01340482 is a Phase 1 study that has completed, run by Kyowa Kirin Co.. The registered enrollment target is 29 participants.
The verdict
NCT01340482, a Phase 1 study, has completed, sponsored by Kyowa Kirin Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
The primary purpose of this study is to assess the safety and efficacy of repeated subcutaneous (SC) injections of KRN23 in adult subjects with X-Linked Hypophosphatemia (XLH). A Bone Substudy will evaluate the effects of single-blind KRN23 versus Placebo on bone mineral density and bone quality.
Interventions
- DRUG KRN23
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2011-04 |
| Est. Completion | 2013-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01340482
The ClinicalTrials.gov registry entry for NCT01340482 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kyowa Kirin Co., which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which KRN23 is the first listed.
NCT01340482 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01340482 about?
NCT01340482 is a clinical study titled "A Repeated Study of KRN23 in Adults With X-Linked Hypophosphatemia". The primary purpose of this study is to assess the safety and efficacy of repeated subcutaneous (SC) injections of KRN23 in adult subjects with X-Linked Hypophosphatemia (XLH). A Bone Substudy will evaluate the effects of single-blind KRN23 versus Placebo on bone mineral density and bone quality.
What is the current status of trial NCT01340482?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2011-04. Estimated completion is 2013-10.
What interventions are being tested in trial NCT01340482?
The interventions under investigation include: KRN23 (DRUG).
Who is sponsoring clinical trial NCT01340482?
This trial is sponsored by Kyowa Kirin Co., which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.